UCLA SPORE in Prostate Cancer

UCLA SPORE 在前列腺癌中的应用

• 批准号: 7879474
• 负责人: ROBERT E REITER
• 金额: $ 230万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7879474
• 关键词: UCLA; SPORE; Prostate; Cancer

The UCLA Prostate Cancer SPORE program is a multidisciplinary and translational research program whose purpose is to understand the biology of prostate cancer and to develop more effective methods for prevention, diagnosis and treatment. This mission will be accomplished through (1) five major research projects focused on the application of basic and population science to the prevention, diagnosis and treatment of prostate cancer, and (2) the recruitment and development of new prostate cancer researchers and research projects through career development and developmental research projects. The UCLA prostate SPORE leverages the exciting resources and programs at UCLA, its sister institutions, as well as Cedars Sinai and City of Hope Cancer Center, to improve the care of men with prostate cancer. It collaborates extensively with other SPORE institutions and the SPORE program at the NCI to advance local and national initiatives. Over the first four years of funding, the UCLA SPORE has made significant strides, such as the development and translation of PSCA antibody therapy to the clinic, the demonstration at the molecular level that mTOR antagonism down-regulates the PIS kinase-PTEN-Akt pathway in men with PTEN null tumors, and the initiation of a novel dietary prevention trial in men undergoing prostate surgery. In this application, the five major projects are as follows: 1) Project 1: Bioengineered Antibodies Against Prostate Stem Cell Antigen (PSCA) for Prostate Cancer Imaging (Project Leaders: Anna Wu, M.D. and Robert Reiter, M.D; Project co-Leader, Robert Figlin, M.D.); 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader: David Agus, M.D.); 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas Cohen, M.D. and Harvey Herschman, Ph.D.)

加州大学洛杉矶分校前列腺癌 SPORE 项目是一个多学科和转化研究项目，其目的是了解前列腺癌的生物学并开发更有效的预防、诊断和治疗方法。这一使命将通过（1）五个主要研究项目重点关注基础科学和人口科学在前列腺癌预防、诊断和治疗中的应用，以及（2）通过职业发展和发展研究项目招募和培养新的前列腺癌研究人员和研究项目。加州大学洛杉矶分校前列腺 SPORE 利用加州大学洛杉矶分校、其姊妹机构以及 Cedars Sinai 和希望之城癌症中心的令人兴奋的资源和项目，来改善前列腺癌男性的护理。它与其他 SPORE 机构和 NCI 的 SPORE 项目广泛合作，以推进地方和国家举措。在资助的前四年中，UCLA SPORE 取得了重大进展，例如 PSCA 抗体疗法的开发和临床转化、在分子水平证明 mTOR 拮抗作用下调 PTEN 缺失肿瘤男性的 PIS 激酶-PTEN-Akt 通路，以及在接受前列腺手术的男性中启动一项新型饮食预防试验。本次申请的五个主要项目如下： 1）项目1：针对前列腺干细胞抗原（PSCA）的生物工程抗体用于前列腺癌成像（项目负责人：Anna Wu，医学博士和Robert Reiter，医学博士；项目共同负责人，Robert Figlin，医学博士）； 2) 项目 2：在前列腺癌中利用 PIS 通路抑制剂治疗（项目负责人：Hong Wu, M.D., Ph.D. 和 Charles Sawyers, M.D；项目共同负责人，Robert Reiter, M..D. 和 Howard Scher, M.D；3）项目 3：前列腺癌的淋巴管生成和转移（项目负责人：Lily Wu，M.D.，Ph.D；项目共同领导者： 大卫·阿古斯，医学博士）； 4) 项目 4：评估 IGFBP-3 疗法在男性前列腺癌中的作用（项目负责人：Pinchas Cohen，医学博士；项目共同负责人：Alan Pantuck，医学博士和 Kuk-Wha Lee，医学博士、哲学博士；5）项目 5：膳食脂肪调节和靶向治疗预防前列腺癌（项目负责人：William Aronson，医学博士；项目共同负责人：Pinchas 科恩医学博士和哈维·赫希曼博士）